From SpringerLink ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1654 of 1668  at  8/19/2020 8:43:10 AM  by

auh2oman


From SpringerLink ...

Interesting and informative abstract on the future advancements in therapy. Here's an excerpt with tilsotolimod  being mentioned:
 
 

The future of combination therapies in advanced melanoma

 
 
 Tilsotolimod (IMO-2125) is a synthetic oligonucleotide which binds to TLR9 and activates antigen presentation of dendritic cells and macrophages with subsequent proliferation of antigen specific cytotoxic T lymphocytes (CD8+ T‑cells) in both injected and uninjected tumors. Tilsotolimod was tested in a phase I/II study in combination with ipilimumab in 26 PD‑1 refractory melanoma patients (NCT02644967). An ORR of 38% with 9.5% CRs was observed which exceeds the expected response rate to ipilimumab alone and the combination was well tolerated [12]. A phase III study with this combination in comparison to ipilimumab alone in PD‑1 refractory patients is ongoing (NCT03445533).
 
 
 
https://link.springer.com/article/10.1007/s12254-020-00640-x
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 143
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1656 Re: From SpringerLink ... vorlon1966 0 9/25/2020 8:01:56 PM






Financial Market Data provided by
.
Loading...